Jonathan Kaufman
Chief Executive Officer, Chairman and President,
Lipella Pharmaceuticals Inc.
United States
Jonathan Kaufman, an experienced biotechnology entrepreneur, is a co-founder of Lipella Pharmaceuticals, Inc., where he currently serves as Chairman and Chief Executive Officer.
Jonathan is a proven innovator in the biotechnology and life science sectors. As Chief Science Officer at LaunchCyte LLC, Jonathan helped create the Reaction Biology Corportation acquired by Cobepa, as well as Knopp Biosciences LLC Inc., which has created multiple pharmaceuticals assets including Dexpramipexole acquired by Areteia Therapeutics and BHV-7000 (a Kv7 activator) acquired by Biohaven.
Jonathan began his career in chemical manufacturing at Merk & Co., Inc., research and development at GSK, and post-doctoral research at the University of Pennsylvania Medical Center.
Jonathan earned a BS in Physics from Carnegie Mellon University, a PhD in Biochemistry and Molecular Biophysics from the University of Pennsylvania School of Medicine, and an MBA in Finance from The Wharton School.
Sessions
-
11-Feb-2025PlymouthLipella Pharmaceuticals Inc.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}